Compare Gilead Sciences, Inc. (GILD) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | QQQE | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $122.72 |
52-Week Low | $110.56 | $96.06 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $123.14, up 0.81% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 companies, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the index, which could drive additional inflows. Technical indicators show strong momentum with ADX readings above 25, though RSI suggests some overbought conditions near-term.
The equal-weight approach offers defensive positioning against tech concentration risks while maintaining Nasdaq growth exposure. Key catalysts include continued tech sector strength and index rebalancing benefits. Risks involve Nasdaq volatility and potential sector rotation away from growth stocks. The ETF's structure provides diversification benefits for investors seeking balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
